M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Rafael Holdings, Inc. to acquire Cyclo Therapeutics, Inc.
Announced Aug 22, 2024 · Closed Mar 26, 2025
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock
Transaction
- Acquirer
- Rafael Holdings, Inc. (RFL)
- Target
- Cyclo Therapeutics, Inc. (CYTH)
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Mar 26, 2025
Deal protections
- Break fee (target pays)
- —
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Not disclosed
- To the target
- Cassel Salpeter
Sector context · Healthcare
- Comparable deals
- 104 in the prior 24 months
- Premium
- Sector median 64.5%
- EV / Adj. EBITDA
- Sector median 17.2x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedAug 22, 2024
- ClosedMar 26, 2025